Tesamorelin and Sermorelin Stack Dosage: What the Research Shows

Tesamorelin and sermorelin can be combined in the same syringe without a known chemical conflict, but there is no established clinical reason to do it. Both are growth hormone-releasing hormone (GHRH) analogs that act on the same pituitary receptor, so the pairing is generally treated as redundant rather than additive. No controlled trial has compared the combination against either peptide given alone.

Is It Worth Stacking Tesamorelin and Sermorelin?

Mechanically, yes - you can stack tesamorelin and sermorelin together, and people on bodybuilding and longevity forums do. The more useful question is whether the second peptide adds anything, and the available pharmacology suggests it does not. Both drugs stimulate the same GHRH receptor on somatotroph cells, and once that receptor is saturated, adding more of the same class tends to produce diminishing returns.

• Same target: both bind the GHRH receptor, so neither adds a new signaling pathway.
• Same endpoints: serum GH and IGF-1 are already what single-agent dosing is judged against.
• No dosing data: there are no published dose-finding studies for the combination.

How the Two Peptides Differ

Tesamorelin is a stabilized, full-length GHRH analog. It is FDA-approved as Egrifta for HIV-associated lipodystrophy and is given as a once-daily subcutaneous injection. Sermorelin is a truncated GHRH fragment (GHRH 1-29) with a much shorter half-life; it is not currently FDA-approved as a marketed product in the United States, and federal rules now restrict compounding it.

That difference matters for scheduling. Tesamorelin's longer action supports once-daily dosing, while sermorelin is usually referenced as a bedtime injection timed to the natural overnight GH pulse.

Feature	Tesamorelin	Sermorelin
Mechanism	GHRH receptor agonist	GHRH receptor agonist
Structure	Stabilized full-length GHRH analog	GHRH fragment (1-29)
FDA status	Approved (Egrifta) for HIV-associated lipodystrophy	No approved marketed product; compounding restricted
Typical single-agent dose	1.4-2 mg subcutaneously once daily	100-300 mcg subcutaneously at bedtime (not FDA-labeled)
Half-life	Roughly 26-38 minutes	Roughly 10-20 minutes

Tesamorelin and Sermorelin Stack Dosage: What Is Actually Referenced

There is no validated tesamorelin and sermorelin stack dosage. What circulates online is usually extrapolated from single-agent labels and older compounding handouts. Any use outside the approved indication is off-label and unregulated.

For context, the FDA-labeled tesamorelin dose is 1.4 mg or 2 mg once daily, depending on the formulation. Sermorelin is commonly referenced at 100-300 mcg before bed in non-clinical discussions. Interest in the aod-9604 tesamorelin stack dosage comes mostly from body-composition forums rather than clinical trials, and the same is true of most combination numbers posted online.

Scenario	Commonly referenced dosing	Evidence level
Tesamorelin alone	1.4-2 mg subcutaneously once daily	FDA label, HIV lipodystrophy only
Sermorelin alone	100-300 mcg subcutaneously at bedtime	Historical and compounded use; no current label
Tesamorelin plus sermorelin	No validated protocol; forum posts suggest splitting daily totals	No clinical data
GHRH analog plus a GHRP such as ipamorelin	GHRH 100 mcg plus GHRP 100-200 mcg, 1-3 times daily	Small studies; still off-label

Why Two GHRH Analogs Compete Instead of Cooperating

Receptor-level logic is the main argument against the stack. GHRH analogs occupy the same binding site, so a second GHRH analog does not open an additional pathway. The pituitary response to GHRH is self-limiting, and supraphysiologic stimulation can blunt later responses rather than amplify them.

Most discussions of the tesamorelin and sermorelin stack end up describing the two peptides as interchangeable options rather than complementary ones. A clinician choosing between them generally picks based on FDA status, cost, and monitoring needs, not on synergy.

Combinations Researchers Actually Study

The better-studied design pairs a GHRH analog with a ghrelin-receptor agonist such as ipamorelin, which works through a different receptor and can act additively. The sermorelin and cjc-1295 stack has the same redundancy problem as the tesamorelin-sermorelin pairing, because CJC-1295 is also a GHRH analog. Searches for cjc-1295 ipamorelin tesamorelin stack dosage usually reflect a GHRH-plus-GHRP design, even when three compounds are named.

Other combinations work through entirely different systems. The tesamorelin and tirzepatide stack is an incretin-based weight-management strategy, and tirzepatide does not act on the pituitary at all. Combining them raises separate questions about blood sugar, appetite, and cost.

Safety, Sourcing, and Legal Status

Tesamorelin is a prescription drug in the U.S. and is approved only for HIV-associated lipodystrophy. Sermorelin has no current FDA-approved marketed product, and regulators have placed it on a list of peptides that cannot be compounded under standard pharmacy rules. Buying either peptide from a website that does not require a prescription means the product is unregulated.

Reported side effects of GHRH analogs include injection-site reactions, fluid retention, joint and muscle pain, and rising blood sugar. Persistently elevated IGF-1 is a monitoring concern, which is why clinicians track labs instead of guessing at doses. Anyone considering these compounds should speak with a licensed healthcare professional first.

Questions to Ask Before Considering a Stack

• Is there a diagnosed condition this is meant to treat?
• What are the baseline IGF-1, fasting glucose, and HbA1c values?
• How often will labs be repeated?
• What is the plan if side effects appear?
• Is the product coming from a licensed pharmacy under a prescription?

For most people, stacking tesamorelin and sermorelin adds cost and risk without adding a documented benefit. If growth hormone stimulation is genuinely indicated, one properly dosed GHRH analog under medical supervision is the more defensible approach.

COMMON QUESTIONS

Frequently Asked Questions

Can you stack tesamorelin and sermorelin together?

You can physically combine them, but the combination is generally considered redundant because both peptides activate the same GHRH receptor. Most clinicians who use GHRH analogs pair them with a ghrelin-receptor agonist such as ipamorelin instead. No clinical trial has compared tesamorelin plus sermorelin against either peptide alone.

What is the standard tesamorelin dosage?

The FDA-labeled dose of tesamorelin (Egrifta) is 1.4 mg or 2 mg injected subcutaneously once daily, depending on the formulation. It is approved only for HIV-associated lipodystrophy. Lower doses used in research settings are not validated for any other indication.

Does stacking two GHRH analogs raise growth hormone more than one?

There is no published evidence that combining two GHRH analogs produces a larger growth hormone or IGF-1 response than an adequate dose of one. Because they compete for the same receptor, the effect is more likely to plateau. Raising the dose also increases the risk of fluid retention, joint pain, and elevated blood sugar.